메뉴 건너뛰기




Volumn 174, Issue 3, 2014, Pages 471-483

Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm

Author keywords

Apixaban; Atrial fibrillation; Dabigatran; Edoxaban; Rivaroxaban; Stroke

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

EID: 84903314967     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.04.179     Document Type: Review
Times cited : (18)

References (110)
  • 1
    • 84868523625 scopus 로고    scopus 로고
    • 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association
    • A.J. Camm, Lip Gy, and R. De Caterina et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
    • (2012) Eur Heart J , vol.33 , pp. 2719-2747
    • Camm, A.J.1    Gy, L.2    De Caterina, R.3
  • 2
    • 84863823405 scopus 로고    scopus 로고
    • The global burden of atrial fibrillation and stroke: A systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe
    • C.M. Lip Gy Brechin, and D.A. Lane The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe Chest 142 6 2012 1489 1498
    • (2012) Chest , vol.142 , Issue.6 , pp. 1489-1498
    • Lip Gy Brechin, C.M.1    Lane, D.A.2
  • 3
    • 0035832261 scopus 로고    scopus 로고
    • Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
    • A.S. Go, E.M. Hylek, and K.A. Phillips et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 18 2001 2370 2375
    • (2001) JAMA , vol.285 , Issue.18 , pp. 2370-2375
    • Go, A.S.1    Hylek, E.M.2    Phillips, K.A.3
  • 4
    • 35248819130 scopus 로고    scopus 로고
    • Atrial fibrillation and stroke prevention
    • G.Y. Lip, and H.S. Lim Atrial fibrillation and stroke prevention Lancet Neurol 6 2007 981 983
    • (2007) Lancet Neurol , vol.6 , pp. 981-983
    • Lip, G.Y.1    Lim, H.S.2
  • 5
    • 20444395760 scopus 로고    scopus 로고
    • Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: Results from a population-based study
    • C. Marini, F. De Santis, and S. Sacco et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study Stroke 36 2005 1115 1119
    • (2005) Stroke , vol.36 , pp. 1115-1119
    • Marini, C.1    De Santis, F.2    Sacco, S.3
  • 6
    • 84855353573 scopus 로고    scopus 로고
    • Heart disease and stroke statistics-2012 update: A report from the American Heart Association
    • G.O.A.S. Roger VL, and D.M. Lloyd-Jones et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association Circulation 125 1 2012 e2 e220
    • (2012) Circulation , vol.125 , Issue.1
    • Roger Vl, G.O.A.S.1    Lloyd-Jones, D.M.2
  • 7
    • 0035854054 scopus 로고    scopus 로고
    • Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation
    • B.F. Gage, A.D. Waterman, and W. Shannon et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
    • (2001) JAMA , vol.285 , pp. 2864-2870
    • Gage, B.F.1    Waterman, A.D.2    Shannon, W.3
  • 8
    • 79551645746 scopus 로고    scopus 로고
    • Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study
    • J.B. Olesen, G.Y. Lip, and M.L. Hansen et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study BMJ 342 2011 d124
    • (2011) BMJ , vol.342 , pp. 124
    • Olesen, J.B.1    Lip, G.Y.2    Hansen, M.L.3
  • 9
    • 84876217465 scopus 로고    scopus 로고
    • Stroke and bleeding risk assessment in atrial fibrillation: When, how, and why?
    • G.Y.H. Lip Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J 34 2013 1041 1049
    • (2013) Eur Heart J , vol.34 , pp. 1041-1049
    • Lip, G.Y.H.1
  • 10
    • 84856745317 scopus 로고    scopus 로고
    • Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    • J.J. You, D.E. Singer, and P.A. Howard et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 e531S e575S
    • (2012) Chest , vol.141 , Issue.2 SUPPL.
    • You, J.J.1    Singer, D.E.2    Howard, P.A.3
  • 11
    • 34347394385 scopus 로고    scopus 로고
    • Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
    • R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
    • (2007) Ann Intern Med , vol.146 , pp. 857-867
    • Hart, R.G.1    Pearce, L.A.2    Aguilar, M.I.3
  • 12
    • 57349097594 scopus 로고    scopus 로고
    • Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon
    • M. Beinema, J.R. Brouwers, T. Schalekamp, and B. Wilff ert Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon Thromb Haemost 100 2008 1052 1057
    • (2008) Thromb Haemost , vol.100 , pp. 1052-1057
    • Beinema, M.1    Brouwers, J.R.2    Schalekamp, T.3    Wilff Ert, B.4
  • 13
    • 77954369172 scopus 로고    scopus 로고
    • New oral anticoagulant drugs in cardiovascular disease
    • I. Ahrens, G.Y.H. Lip, and K. Peter New oral anticoagulant drugs in cardiovascular disease Thromb Haemost 104 2010 49 60
    • (2010) Thromb Haemost , vol.104 , pp. 49-60
    • Ahrens, I.1    Lip, G.Y.H.2    Peter, K.3
  • 14
    • 2942541131 scopus 로고    scopus 로고
    • SAFE II Investigators Stroke prevention and atrial fibrillation: Reasons leading to an inappropriate management. Main results of the SAFE II study
    • D. Deplanque, D. Leys, and L. Parnetti et al. SAFE II Investigators Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study Br J Clin Pharmacol 57 6 2004 798 806
    • (2004) Br J Clin Pharmacol , vol.57 , Issue.6 , pp. 798-806
    • Deplanque, D.1    Leys, D.2    Parnetti, L.3
  • 15
    • 31944446445 scopus 로고    scopus 로고
    • Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry
    • M.R. Reynolds, J. Shah, and V. Essebag et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry Am J Cardiol 97 4 2006 538 543
    • (2006) Am J Cardiol , vol.97 , Issue.4 , pp. 538-543
    • Reynolds, M.R.1    Shah, J.2    Essebag, V.3
  • 16
    • 35548961833 scopus 로고    scopus 로고
    • Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation
    • N.M. Allen LaPointe, L. Governale, J. Watkins, J. Mulgund, and K.J. Anstrom Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation Am Heart J 154 5 2007 893 898
    • (2007) Am Heart J , vol.154 , Issue.5 , pp. 893-898
    • Allen Lapointe, N.M.1    Governale, L.2    Watkins, J.3    Mulgund, J.4    Anstrom, K.J.5
  • 17
    • 0033593072 scopus 로고    scopus 로고
    • Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study
    • A.S. Go, E.M. Hylek, L.H. Borowsky, K.A. Phillips, J.V. Selby, and D.E. Singer Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Ann Intern Med 131 12 1999 927 934
    • (1999) Ann Intern Med , vol.131 , Issue.12 , pp. 927-934
    • Go, A.S.1    Hylek, E.M.2    Borowsky, L.H.3    Phillips, K.A.4    Selby, J.V.5    Singer, D.E.6
  • 18
    • 45949098057 scopus 로고    scopus 로고
    • American College of Chest Physicians: Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    • S. Schulman, R.J. Beyth, C. Kearon, and M.N. Levine American College of Chest Physicians: hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 6 2008 257S 298S
    • (2008) Chest , vol.133 , Issue.6
    • Schulman, S.1    Beyth, R.J.2    Kearon, C.3    Levine, M.N.4
  • 19
    • 38749131205 scopus 로고    scopus 로고
    • The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
    • S. Blech, T. Ebner, E. Ludwig-Schwellinger, J. Stangier, and W. Roth The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans Drug Metab Dispos 36 2008 386 389
    • (2008) Drug Metab Dispos , vol.36 , pp. 386-389
    • Blech, S.1    Ebner, T.2    Ludwig-Schwellinger, E.3    Stangier, J.4    Roth, W.5
  • 20
    • 66449099711 scopus 로고    scopus 로고
    • Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans
    • O. Weinz, T. Schwarz, D. Kubitza, W. Mueck, and D. Lang Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans Drug Metab Dispos 37 2009 1056 1064
    • (2009) Drug Metab Dispos , vol.37 , pp. 1056-1064
    • Weinz, O.1    Schwarz, T.2    Kubitza, D.3    Mueck, W.4    Lang, D.5
  • 21
    • 58149458160 scopus 로고    scopus 로고
    • Apixaban metabolism and pharmacokinetics after oral administration to humans
    • N. Raghavan, C.E. Frost, and z Yu et al. Apixaban metabolism and pharmacokinetics after oral administration to humans Drug Metab Dispos 37 2009 74 81
    • (2009) Drug Metab Dispos , vol.37 , pp. 74-81
    • Raghavan, N.1    Frost, C.E.2    Yu, Z.3
  • 22
    • 77953787643 scopus 로고    scopus 로고
    • Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers
    • K. Ogata, J. Mendell-Harary, and M. Tachibana Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers J Clin Pharmacol 50 7 2010 743 753
    • (2010) J Clin Pharmacol , vol.50 , Issue.7 , pp. 743-753
    • Ogata, K.1    Mendell-Harary, J.2    Tachibana, M.3
  • 23
    • 84869109465 scopus 로고    scopus 로고
    • Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans
    • M.S. Bathala, H. Masumoto, T. Oguma, L. He, C. Lowrie, and J. Mendell Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans Drug Metab Dispos 40 12 2012 2250 2255
    • (2012) Drug Metab Dispos , vol.40 , Issue.12 , pp. 2250-2255
    • Bathala, M.S.1    Masumoto, H.2    Oguma, T.3    He, L.4    Lowrie, C.5    Mendell, J.6
  • 24
    • 84877301336 scopus 로고    scopus 로고
    • European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
    • H. Heidbuchel, P. Verhamme, and M. Alings et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
    • (2013) Europace , vol.15 , pp. 625-651
    • Heidbuchel, H.1    Verhamme, P.2    Alings, M.3
  • 25
    • 84891820486 scopus 로고    scopus 로고
    • A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors
    • M. Crowther, M. Vandana, and K. Michael et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors Abstract #3636; American Society of Hematology 55th Annual Meeting 2013
    • (2013) Abstract #3636; American Society of Hematology 55th Annual Meeting
    • Crowther, M.1    Vandana, M.2    Michael, K.3
  • 26
    • 84910112018 scopus 로고    scopus 로고
    • A specific antidote for dabigatran: Immediate, complete and sustained reversal of dabigatran-induced anticoagulation in healthy male volunteers
    • S. Glund, J. Stangier, and M. Schmohl et al. A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran-induced anticoagulation in healthy male volunteers Abstract #17765; American Heart Association's Scientific Sessions 2013
    • (2013) Abstract #17765; American Heart Association's Scientific Sessions
    • Glund, S.1    Stangier, J.2    Schmohl, M.3
  • 27
    • 84882247210 scopus 로고    scopus 로고
    • Bleeding and antidotes in new oral anticoagulants
    • A. Majeed, and S. Schulman Bleeding and antidotes in new oral anticoagulants Best Pract Res Clin Haematol 26 2013 191 202
    • (2013) Best Pract Res Clin Haematol , vol.26 , pp. 191-202
    • Majeed, A.1    Schulman, S.2
  • 28
    • 70349306707 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with atrial fibrillation
    • S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
    • (2009) N Engl J Med , vol.361 , pp. 1139-1151
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 29
    • 80052592404 scopus 로고    scopus 로고
    • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    • M.R. Patel, K.W. Mahaffey, and J. Garg et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
    • (2011) N Engl J Med , vol.365 , pp. 883-891
    • Patel, M.R.1    Mahaffey, K.W.2    Garg, J.3
  • 30
    • 80052825103 scopus 로고    scopus 로고
    • Apixaban versus warfarin in patients with atrial fibrillation
    • C.B. Granger, J.H. Alexander, and J.J. McMurray et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
    • (2011) N Engl J Med , vol.365 , pp. 981-992
    • Granger, C.B.1    Alexander, J.H.2    McMurray, J.J.3
  • 31
    • 84888362796 scopus 로고    scopus 로고
    • Edoxaban versus warfarin in patients with atrial fibrillation
    • R.P. Giugliano, C.T. Ruff, and E. Braunwald et al. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
    • (2013) N Engl J Med , vol.369 , pp. 2093-2104
    • Giugliano, R.P.1    Ruff, C.T.2    Braunwald, E.3
  • 32
    • 77949312944 scopus 로고    scopus 로고
    • Drug-induced liver injury in humans: The case of ximelagatran
    • M. Keisu, and T.B. Andersson Drug-induced liver injury in humans: the case of ximelagatran Handb Exp Pharmacol 196 2010 407 418
    • (2010) Handb Exp Pharmacol , vol.196 , pp. 407-418
    • Keisu, M.1    Andersson, T.B.2
  • 33
    • 78049490509 scopus 로고    scopus 로고
    • Newly identified events in the RE-LY trial
    • S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. Newly identified events in the RE-LY trial N Engl J Med 363 2010 1875 1876
    • (2010) N Engl J Med , vol.363 , pp. 1875-1876
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 34
    • 84857021520 scopus 로고    scopus 로고
    • Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials
    • K. Uchino, and A.V. Hernandez Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials Arch Intern Med 172 2012 397 402
    • (2012) Arch Intern Med , vol.172 , pp. 397-402
    • Uchino, K.1    Hernandez, A.V.2
  • 35
    • 84858595913 scopus 로고    scopus 로고
    • Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: Recommendations for stroke prevention and rate/rhythm control
    • A.C. Skanes, J.S. Healey, and J.A. Cairns et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control Can J Cardiol 28 2012 125 136
    • (2012) Can J Cardiol , vol.28 , pp. 125-136
    • Skanes, A.C.1    Healey, J.S.2    Cairns, J.A.3
  • 36
    • 84865138532 scopus 로고    scopus 로고
    • Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation
    • G.Y.H. Lip, T.B. Larsen, F. Skjoth, and L.H. Rasmussen Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation J Am Coll Cardiol 60 2012 738 746
    • (2012) J Am Coll Cardiol , vol.60 , pp. 738-746
    • Lip, G.Y.H.1    Larsen, T.B.2    Skjoth, F.3    Rasmussen, L.H.4
  • 37
    • 84865808575 scopus 로고    scopus 로고
    • An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation
    • S. Mantha, and J. Ansell An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation Thromb Haemost 108 2012 476 484
    • (2012) Thromb Haemost , vol.108 , pp. 476-484
    • Mantha, S.1    Ansell, J.2
  • 38
    • 84865807336 scopus 로고    scopus 로고
    • Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network metaanalysis
    • J. Harenberg et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network metaanalysis Int Angiol 31 2012 330 339
    • (2012) Int Angiol , vol.31 , pp. 330-339
    • Harenberg, J.1
  • 39
    • 84868664103 scopus 로고    scopus 로고
    • Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation
    • W.L. Baker, and O.J. Phung Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation Circ Cardiovasc Qual Outcomes 5 2012 711 719
    • (2012) Circ Cardiovasc Qual Outcomes , vol.5 , pp. 711-719
    • Baker, W.L.1    Phung, O.J.2
  • 40
    • 84865041123 scopus 로고    scopus 로고
    • Stroke and bleeding in atrial fibrillation with chronic kidney disease
    • J.B. Olesen, G.Y. Lip, and A.L. Kamper et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease N Engl J Med 367 2012 625 635
    • (2012) N Engl J Med , vol.367 , pp. 625-635
    • Olesen, J.B.1    Lip, G.Y.2    Kamper, A.L.3
  • 41
    • 84872345697 scopus 로고    scopus 로고
    • Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation validation of the R2CHADS2 index in the ROCKET AF
    • (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors in Atrial fibrillation) study cohorts
    • J.P. Piccini, S.R. Stevens, and Y.C. Chang et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts Circulation 127 2013 224 232
    • (2013) Circulation , vol.127 , pp. 224-232
    • Piccini, J.P.1    Stevens, S.R.2    Chang, Y.C.3
  • 42
    • 79952662118 scopus 로고    scopus 로고
    • Severe renal impairment and stroke prevention in atrial fibrillation
    • R. Marinigh, D.A. Lane, and G.Y.H. Lip Severe renal impairment and stroke prevention in atrial fibrillation J Am Coll Cardiol 57 2011 1339 1348
    • (2011) J Am Coll Cardiol , vol.57 , pp. 1339-1348
    • Marinigh, R.1    Lane, D.A.2    Lip, G.Y.H.3
  • 43
    • 77955872745 scopus 로고    scopus 로고
    • A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey
    • R. Pisters, D.A. Lane, and R. Nieuwlaat et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
    • (2010) Chest , vol.138 , pp. 1093-1100
    • Pisters, R.1    Lane, D.A.2    Nieuwlaat, R.3
  • 44
    • 78650878679 scopus 로고    scopus 로고
    • Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score
    • G.Y.H. Lip, L. Frison, and J.L. Halperin et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score J Am Coll Cardiol 57 2011 173 180
    • (2011) J Am Coll Cardiol , vol.57 , pp. 173-180
    • Lip, G.Y.H.1    Frison, L.2    Halperin, J.L.3
  • 45
    • 80052426052 scopus 로고    scopus 로고
    • Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a "real world" nationwide cohort study
    • J.B. Olesen, Lip Gy, and J. Lindhardsen et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a "real world" nationwide cohort study Thromb Haemost 106 2011 739 749
    • (2011) Thromb Haemost , vol.106 , pp. 739-749
    • Olesen, J.B.1    Gy, L.2    Lindhardsen, J.3
  • 46
    • 84859703006 scopus 로고    scopus 로고
    • Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment
    • M.K. Wychowski, and P.A. Kouides Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment Ann Pharmacother 46 2012 e10
    • (2012) Ann Pharmacother , vol.46 , pp. 10
    • Wychowski, M.K.1    Kouides, P.A.2
  • 47
    • 79960955075 scopus 로고    scopus 로고
    • The use of dabigatran in elderly patients
    • M. Legrand, J. Mateo, and A. Aribaud et al. The use of dabigatran in elderly patients Arch Intern Med 171 14 2011 1285 1286
    • (2011) Arch Intern Med , vol.171 , Issue.14 , pp. 1285-1286
    • Legrand, M.1    Mateo, J.2    Aribaud, A.3
  • 48
    • 84857853180 scopus 로고    scopus 로고
    • Bleeding risk with dabigatran in the frail elderly
    • P. Harper, L. Young, and E. Merriman Bleeding risk with dabigatran in the frail elderly N Engl J Med 366 9 2012 864 866
    • (2012) N Engl J Med , vol.366 , Issue.9 , pp. 864-866
    • Harper, P.1    Young, L.2    Merriman, E.3
  • 49
    • 84869100588 scopus 로고    scopus 로고
    • Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial
    • S.H. Hohnloser, Z. Hijazi, and L. Thomas et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial Eur Heart J 33 2012 2821 2830
    • (2012) Eur Heart J , vol.33 , pp. 2821-2830
    • Hohnloser, S.H.1    Hijazi, Z.2    Thomas, L.3
  • 50
    • 80054071757 scopus 로고    scopus 로고
    • Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
    • K.A.A. Fox, J.P. Piccini, and D. Wojdyla et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment Eur Heart J 32 2011 2387 2394
    • (2011) Eur Heart J , vol.32 , pp. 2387-2394
    • Fox, K.A.A.1    Piccini, J.P.2    Wojdyla, D.3
  • 51
    • 0023625745 scopus 로고
    • Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study
    • P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study Arch Intern Med 147 1987 1561 1564
    • (1987) Arch Intern Med , vol.147 , pp. 1561-1564
    • Wolf, P.A.1    Abbott, R.D.2    Kannel, W.B.3
  • 52
    • 0027291892 scopus 로고
    • Bleeding complications in oral anticoagulant therapy. An analysis of risk factors
    • F.J. Van der Meer, F.R. Rosendaal, and J.P. Vandenbroucke et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors Arch Intern Med 153 1993 1557 1562
    • (1993) Arch Intern Med , vol.153 , pp. 1557-1562
    • Van Der Meer, F.J.1    Rosendaal, F.R.2    Vandenbroucke, J.P.3
  • 53
    • 34249715284 scopus 로고    scopus 로고
    • Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation
    • E.M. Hylek, C. Evans-Molina, C. Shea, L.E. Henault, and S. Regan Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 115 2007 2689 2696
    • (2007) Circulation , vol.115 , pp. 2689-2696
    • Hylek, E.M.1    Evans-Molina, C.2    Shea, C.3    Henault, L.E.4    Regan, S.5
  • 54
    • 34547433185 scopus 로고    scopus 로고
    • Death and disability from warfarin-associated intracranial and extracranial hemorrhages
    • M.C. Fang, A.S. Go, and Y. Chang et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages Am J Med 120 2007 700 705
    • (2007) Am J Med , vol.120 , pp. 700-705
    • Fang, M.C.1    Go, A.S.2    Chang, Y.3
  • 55
    • 0035092938 scopus 로고    scopus 로고
    • Risk factors for hospitalized gastrointestinal bleeding among older persons
    • R.C. Kaplan, S.R. Heckbert, and T.D. Koespell et al. Risk factors for hospitalized gastrointestinal bleeding among older persons J Am Geriatr Soc 49 2001 126 133
    • (2001) J Am Geriatr Soc , vol.49 , pp. 126-133
    • Kaplan, R.C.1    Heckbert, S.R.2    Koespell, T.D.3
  • 56
    • 33645828603 scopus 로고    scopus 로고
    • Translating the results of randomized trials into clinical practice: The challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation
    • E.M. Hylek, J. D'Antonio, and C. Evans-Molina et al. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation Stroke 37 2006 1075 1080
    • (2006) Stroke , vol.37 , pp. 1075-1080
    • Hylek, E.M.1    D'Antonio, J.2    Evans-Molina, C.3
  • 57
    • 80053073829 scopus 로고    scopus 로고
    • Attitudes of physicians regarding anticoagulation for atrial fibrillation: A systematic review
    • D. Pugh, J. Pugh, and G.E. Mead Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review Age Ageing 40 6 2011 675 683
    • (2011) Age Ageing , vol.40 , Issue.6 , pp. 675-683
    • Pugh, D.1    Pugh, J.2    Mead, G.E.3
  • 58
    • 38149133353 scopus 로고    scopus 로고
    • Barriers to anticoagulation in patients with atrial fibrillation: Changing physician-related factors
    • D.A. Lane, and G.Y. Lip Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors Stroke 39 1 2008 7 9
    • (2008) Stroke , vol.39 , Issue.1 , pp. 7-9
    • Lane, D.A.1    Lip, G.Y.2
  • 59
    • 14844352048 scopus 로고    scopus 로고
    • Predictors of anticoagulation prescription in nursing home residents with atrial fibrillation
    • A.K. Abdel-Latif, X. Peng, and B.J. Messinger-Rapport Predictors of anticoagulation prescription in nursing home residents with atrial fibrillation J Am Med Dir Assoc 6 2 2005 128 131
    • (2005) J Am Med Dir Assoc , vol.6 , Issue.2 , pp. 128-131
    • Abdel-Latif, A.K.1    Peng, X.2    Messinger-Rapport, B.J.3
  • 60
    • 27144528554 scopus 로고    scopus 로고
    • Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system
    • T. Darkow, A.M. Vanderplas, and K.H. Lew et al. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system Curr Med Res Opin 21 2005 1583 1594
    • (2005) Curr Med Res Opin , vol.21 , pp. 1583-1594
    • Darkow, T.1    Vanderplas, A.M.2    Lew, K.H.3
  • 61
    • 27444435844 scopus 로고    scopus 로고
    • NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation
    • A.L. Waldo, R.C. Becker, and V.F. Tapson et al. NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation J Am Coll Cardiol 46 2005 172917 172936
    • (2005) J Am Coll Cardiol , vol.46 , pp. 172917-172936
    • Waldo, A.L.1    Becker, R.C.2    Tapson, V.F.3
  • 62
    • 33947413877 scopus 로고    scopus 로고
    • A randomised controlled trial of warfarin versus aspirin for stroke prevention on octogenarians with AF (WASPO)
    • A. Rash, T. Downes, and R. Portner et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention on octogenarians with AF (WASPO) Age Ageing 36 2007 151 156
    • (2007) Age Ageing , vol.36 , pp. 151-156
    • Rash, A.1    Downes, T.2    Portner, R.3
  • 63
    • 34547693119 scopus 로고    scopus 로고
    • Warfarin versus aspirin for stroke prevention in an elderly community population with AF (the Birmingham AF Treatment of the Aged Study BAFTA): A randomised controlled trial
    • J. Mant, R. Hobbs, and K. Fletcher et al. Warfarin versus aspirin for stroke prevention in an elderly community population with AF (the Birmingham AF Treatment of the Aged Study BAFTA): a randomised controlled trial Lancet 370 2007 493 503
    • (2007) Lancet , vol.370 , pp. 493-503
    • Mant, J.1    Hobbs, R.2    Fletcher, K.3
  • 65
    • 79958126202 scopus 로고    scopus 로고
    • Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial
    • J.W. Eikelboom, L. Wallentin, and S.J. Connolly et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial Circulation 123 21 2011 2363 2372
    • (2011) Circulation , vol.123 , Issue.21 , pp. 2363-2372
    • Eikelboom, J.W.1    Wallentin, L.2    Connolly, S.J.3
  • 66
    • 84879096748 scopus 로고    scopus 로고
    • Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular AF in the ROCKET-AF trial
    • J.L. Halperin, D. Wojdyla, and J.P. Piccini et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular AF in the ROCKET-AF trial Stroke 43 2012 A148
    • (2012) Stroke , vol.43 , pp. 148
    • Halperin, J.L.1    Wojdyla, D.2    Piccini, J.P.3
  • 67
    • 84869083231 scopus 로고    scopus 로고
    • Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: A secondary analysis of a randomized controlled trial
    • R.D. Lopes, S.M. Al-Khatib, and L. Wallentin et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial Lancet 380 9855 2012 1749 1758
    • (2012) Lancet , vol.380 , Issue.9855 , pp. 1749-1758
    • Lopes, R.D.1    Al-Khatib, S.M.2    Wallentin, L.3
  • 68
    • 84866368808 scopus 로고    scopus 로고
    • 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
    • H. Jneid, J.L. Anderson, and R.S. Wright et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 60 2012 645 681
    • (2012) J Am Coll Cardiol , vol.60 , pp. 645-681
    • Jneid, H.1    Anderson, J.L.2    Wright, R.S.3
  • 69
    • 84855992555 scopus 로고    scopus 로고
    • 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive summary
    • G.N. Levine, E.R. Bates, and J.C. Blankenship et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary J Am Coll Cardiol 58 2011 e44 e122
    • (2011) J Am Coll Cardiol , vol.58
    • Levine, G.N.1    Bates, E.R.2    Blankenship, J.C.3
  • 70
    • 84872698656 scopus 로고    scopus 로고
    • 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
    • P.T. O'Gara, F.G. Kushner, and D.D. Ascheim et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
    • (2013) J Am Coll Cardiol , vol.61
    • O'Gara, P.T.1    Kushner, F.G.2    Ascheim, D.D.3
  • 71
    • 77953189870 scopus 로고    scopus 로고
    • Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: Executive summary - A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
    • G.Y. Lip, K. Huber, and F. Andreotti et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary - a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 31 2010 1311 1318
    • (2010) Eur Heart J , vol.31 , pp. 1311-1318
    • Lip, G.Y.1    Huber, K.2    Andreotti, F.3
  • 72
    • 82955229534 scopus 로고    scopus 로고
    • Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: A North American perspective: Executive summary
    • D. Faxon, J. Eikelboom, and P. Berger et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary Circ Cardiovasc Interv 4 2011 522 534
    • (2011) Circ Cardiovasc Interv , vol.4 , pp. 522-534
    • Faxon, D.1    Eikelboom, J.2    Berger, P.3
  • 73
    • 67649414486 scopus 로고    scopus 로고
    • Combining antiplatelet and anticoagulant therapies
    • D.R. Holmes, D.J. Kereiakes, and N.S. Kleiman et al. Combining antiplatelet and anticoagulant therapies J Am Coll Cardiol 54 2009 95 109
    • (2009) J Am Coll Cardiol , vol.54 , pp. 95-109
    • Holmes, D.R.1    Kereiakes, D.J.2    Kleiman, N.S.3
  • 74
    • 79952816422 scopus 로고    scopus 로고
    • Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation
    • F. Gao, Y.J. Zhou, and Z.J. Wang et al. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation Int J Cardiol 148 2011 96 101
    • (2011) Int J Cardiol , vol.148 , pp. 96-101
    • Gao, F.1    Zhou, Y.J.2    Wang, Z.J.3
  • 75
    • 79551592248 scopus 로고    scopus 로고
    • "Triple therapy" rather than "triple threat": A meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment
    • H.J. Zhao, Z.T. Zheng, and Z.H. Wang et al. "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment Chest 139 2011 260 270
    • (2011) Chest , vol.139 , pp. 260-270
    • Zhao, H.J.1    Zheng, Z.T.2    Wang, Z.H.3
  • 76
    • 84875720372 scopus 로고    scopus 로고
    • Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial
    • W.J. Dewilde, T. Oirbans, and F.W. Verheugt et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 2013 1107 1115
    • (2013) Lancet , vol.381 , pp. 1107-1115
    • Dewilde, W.J.1    Oirbans, T.2    Verheugt, F.W.3
  • 77
    • 84865863475 scopus 로고    scopus 로고
    • Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention. A nation cohort study
    • M. Lamberts, J.B. Olesen, and M.H. Ruwald et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention. A nation cohort study Circulation 126 2012 1185 1193
    • (2012) Circulation , vol.126 , pp. 1185-1193
    • Lamberts, M.1    Olesen, J.B.2    Ruwald, M.H.3
  • 78
    • 84865864223 scopus 로고    scopus 로고
    • Acute coronary syndrome in patients with atrial fibrillation. What is the benefit/risk profile of triple antithrombotic therapy?
    • A.P. Maggioni Acute coronary syndrome in patients with atrial fibrillation. What is the benefit/risk profile of triple antithrombotic therapy? Circulation 126 2012 1176 1178
    • (2012) Circulation , vol.126 , pp. 1176-1178
    • Maggioni, A.P.1
  • 79
    • 84862907587 scopus 로고    scopus 로고
    • Rivaroxaban in patients with a recent acute coronary syndrome
    • J.L. Mega, E. Braunwald, and S.D. Wiviott et al. Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
    • (2012) N Engl J Med , vol.366 , pp. 9-19
    • Mega, J.L.1    Braunwald, E.2    Wiviott, S.D.3
  • 80
    • 80052162121 scopus 로고    scopus 로고
    • Apixaban with antiplatelet therapy after acute coronary syndrome
    • J.H. Alexander, R.D. Lopes, and S. James et al. Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
    • (2011) N Engl J Med , vol.365 , pp. 699-708
    • Alexander, J.H.1    Lopes, R.D.2    James, S.3
  • 82
    • 84859509560 scopus 로고    scopus 로고
    • 2012 HRS/EHRA/ECAS Expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design
    • H. Calkins, K.H. Kuck, and R. Cappato et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design Europace 14 2012 528 606
    • (2012) Europace , vol.14 , pp. 528-606
    • Calkins, H.1    Kuck, K.H.2    Cappato, R.3
  • 83
    • 77649308976 scopus 로고    scopus 로고
    • Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation
    • R. Cappato, H. Calkins, and S.A. Chen et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation Circ Arrhythm Electrophysiol 3 2010 32 38
    • (2010) Circ Arrhythm Electrophysiol , vol.3 , pp. 32-38
    • Cappato, R.1    Calkins, H.2    Chen, S.A.3
  • 84
    • 84862240330 scopus 로고    scopus 로고
    • Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: Evidence from a meta-analysis
    • P. Santangeli, L. Di Biase, and R. Horton et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis Circ Arrhythm Electrophysiol 5 2012 302 311
    • (2012) Circ Arrhythm Electrophysiol , vol.5 , pp. 302-311
    • Santangeli, P.1    Di Biase, L.2    Horton, R.3
  • 85
    • 84899094874 scopus 로고    scopus 로고
    • Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: Results from the COMPARE randomized trial
    • L. Di Biase, J.D. Burkhardt, and P. Santangeli et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the COMPARE randomized trial Heart Rhythm 34th Annual Scientific Sessions 2013
    • (2013) Heart Rhythm 34th Annual Scientific Sessions
    • Di Biase, L.1    Burkhardt, J.D.2    Santangeli, P.3
  • 86
    • 84858709300 scopus 로고    scopus 로고
    • Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation
    • D. Lakkireddy, Y.M. Reddy, and L. Di Base et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation J Am Coll Cardiol 59 2012 1168 1174
    • (2012) J Am Coll Cardiol , vol.59 , pp. 1168-1174
    • Lakkireddy, D.1    Reddy, Y.M.2    Di Base, L.3
  • 87
    • 84875753938 scopus 로고    scopus 로고
    • Dabigatran versus warfarin for radiofrequency catheter ablation of atrial fibrillation
    • J.S. Kim, K. Jongnarangsin, and A. Chugh et al. Dabigatran versus warfarin for radiofrequency catheter ablation of atrial fibrillation Heart Rhythm 10 2013 483 489
    • (2013) Heart Rhythm , vol.10 , pp. 483-489
    • Kim, J.S.1    Jongnarangsin, K.2    Chugh, A.3
  • 88
    • 84878702358 scopus 로고    scopus 로고
    • Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation
    • H. Yamaji, T. Murakami, and K. Hina et al. Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation Clin Drug Investig 33 2013 409 418
    • (2013) Clin Drug Investig , vol.33 , pp. 409-418
    • Yamaji, H.1    Murakami, T.2    Hina, K.3
  • 89
    • 84882251208 scopus 로고    scopus 로고
    • Use of dabigatran for peri-procedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation
    • M. Bassiouny, W. Saliba, and J. Rickard et al. Use of dabigatran for peri-procedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation Circ Arrhythm Electrophysiol 6 2013 460 466
    • (2013) Circ Arrhythm Electrophysiol , vol.6 , pp. 460-466
    • Bassiouny, M.1    Saliba, W.2    Rickard, J.3
  • 90
    • 84885012489 scopus 로고    scopus 로고
    • Novel oral anticoagulation in a real world cohort of patients undergoing catheter ablation of atrial fibrillation
    • C. Eitel, J. Koch, and P. Sommer et al. Novel oral anticoagulation in a real world cohort of patients undergoing catheter ablation of atrial fibrillation Europace 15 2013 1587 1593
    • (2013) Europace , vol.15 , pp. 1587-1593
    • Eitel, C.1    Koch, J.2    Sommer, P.3
  • 91
    • 84880635046 scopus 로고    scopus 로고
    • Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation
    • W. Maddox, G.N. Kay, and T. Yamada et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation J Cardiovasc Electrophysiol 24 2013 861 865
    • (2013) J Cardiovasc Electrophysiol , vol.24 , pp. 861-865
    • Maddox, W.1    Kay, G.N.2    Yamada, T.3
  • 92
    • 84885002072 scopus 로고    scopus 로고
    • Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: A meta-analysis of the literature
    • S.H. Hohnloser, and A.J. Camm Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature Europace 15 2013 1407 1411
    • (2013) Europace , vol.15 , pp. 1407-1411
    • Hohnloser, S.H.1    Camm, A.J.2
  • 93
    • 84884997616 scopus 로고    scopus 로고
    • Safety and efficacy of interrupted dabigatran for per-procedural anticoagulation in catheter ablation of atrial fibrillation: A systematic review and meta-analysis
    • A.A.B. Abdulhak, A.R. Khan, and I.M. Tleyjeh et al. Safety and efficacy of interrupted dabigatran for per-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis Europace 15 2013 1412 1420
    • (2013) Europace , vol.15 , pp. 1412-1420
    • Abdulhak, A.A.B.1    Khan, A.R.2    Tleyjeh, I.M.3
  • 94
    • 84863989146 scopus 로고    scopus 로고
    • Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin
    • J.S. Healey, J. Eikelboom, and J. Douketis et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin Circulation 126 2012 343 348
    • (2012) Circulation , vol.126 , pp. 343-348
    • Healey, J.S.1    Eikelboom, J.2    Douketis, J.3
  • 95
    • 84875912864 scopus 로고    scopus 로고
    • General mechanisms of coagulation and targets of anticoagulants (section I): Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease
    • R. De Caterina, S. Husted, and L. Wallentin et al. General mechanisms of coagulation and targets of anticoagulants (section I): position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Thromb Haemost 109 2013 569 579
    • (2013) Thromb Haemost , vol.109 , pp. 569-579
    • De Caterina, R.1    Husted, S.2    Wallentin, L.3
  • 96
    • 80155179455 scopus 로고    scopus 로고
    • Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients
    • A.M. Gallagher, E. Setakis, J.M. Plumb, A. Clemens, and T.P. van Staa Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients Thromb Haemost 106 2011 968 977
    • (2011) Thromb Haemost , vol.106 , pp. 968-977
    • Gallagher, A.M.1    Setakis, E.2    Plumb, J.M.3    Clemens, A.4    Van Staa, T.P.5
  • 97
    • 70349657518 scopus 로고    scopus 로고
    • Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: A systematic review
    • Y. Wan, C. Heneghan, and R. Perera et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review Circ Cardiovasc Qual Outcomes 1 2008 84 91
    • (2008) Circ Cardiovasc Qual Outcomes , vol.1 , pp. 84-91
    • Wan, Y.1    Heneghan, C.2    Perera, R.3
  • 98
    • 84878567148 scopus 로고    scopus 로고
    • Apixaban compared with warfarin for stroke prevention in atrial fibrillation. Implications of time in therapeutic range
    • P. Gallego, J.A. Vilchez, and D.A. Lane Apixaban compared with warfarin for stroke prevention in atrial fibrillation. Implications of time in therapeutic range Circulation 127 2013 2163 2165
    • (2013) Circulation , vol.127 , pp. 2163-2165
    • Gallego, P.1    Vilchez, J.A.2    Lane, D.A.3
  • 99
    • 77956977472 scopus 로고    scopus 로고
    • Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial
    • L. Wallentin, S. Yusuf, and M.D. Ezekowitz et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 376 2010 975 983
    • (2010) Lancet , vol.376 , pp. 975-983
    • Wallentin, L.1    Yusuf, S.2    Ezekowitz, M.D.3
  • 100
    • 84878535107 scopus 로고    scopus 로고
    • Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation
    • L. Wallentin, R.D. Lopes, and M. Hanna et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation Circulation 127 2013 2166 2176
    • (2013) Circulation , vol.127 , pp. 2166-2176
    • Wallentin, L.1    Lopes, R.D.2    Hanna, M.3
  • 101
    • 84860483079 scopus 로고    scopus 로고
    • The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study
    • J.B. Olesen, C. Torp-Pedersen, and M.L. Hansen et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study Thromb Haemost 107 2012 1172 1179
    • (2012) Thromb Haemost , vol.107 , pp. 1172-1179
    • Olesen, J.B.1    Torp-Pedersen, C.2    Hansen, M.L.3
  • 102
    • 84872551383 scopus 로고    scopus 로고
    • The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulation
    • M. Coppens, J.W. Eikelboom, and R.G. Hart et al. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulation Eur Heart J 34 2013 170 176
    • (2013) Eur Heart J , vol.34 , pp. 170-176
    • Coppens, M.1    Eikelboom, J.W.2    Hart, R.G.3
  • 103
    • 84887429728 scopus 로고    scopus 로고
    • Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin
    • S. Apostolakis, R.M. Sullivan, B. Olshansky, and G.Y.H. Lip Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin Chest 144 2013 1555 1563
    • (2013) Chest , vol.144 , pp. 1555-1563
    • Apostolakis, S.1    Sullivan, R.M.2    Olshansky, B.3    Lip, G.Y.H.4
  • 104
    • 84895546731 scopus 로고    scopus 로고
    • Factors associated with major bleeding events: Insights from the Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
    • S.G. Goodman, D.M. Wojdyla, and J.P. Piccini et al. Factors associated with major bleeding events: insights from the Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) J Am Coll Cardiol 63 2014 891 900
    • (2014) J Am Coll Cardiol , vol.63 , pp. 891-900
    • Goodman, S.G.1    Wojdyla, D.M.2    Piccini, J.P.3
  • 105
    • 79958813704 scopus 로고    scopus 로고
    • Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation
    • S.V. Shah, and B.F. Gage Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Circulation 123 2011 2562 2570
    • (2011) Circulation , vol.123 , pp. 2562-2570
    • Shah, S.V.1    Gage, B.F.2
  • 106
    • 79955774273 scopus 로고    scopus 로고
    • Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective
    • S.V. Sorensen, A.R. Kansal, and S. Connolly et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective Thromb Haemost 105 2011 908 919
    • (2011) Thromb Haemost , vol.105 , pp. 908-919
    • Sorensen, S.V.1    Kansal, A.R.2    Connolly, S.3
  • 107
    • 84858598110 scopus 로고    scopus 로고
    • Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
    • A.R. Kansal, S.V. Sorensen, and R. Gani et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation Heart 98 7 2012 573 578
    • (2012) Heart , vol.98 , Issue.7 , pp. 573-578
    • Kansal, A.R.1    Sorensen, S.V.2    Gani, R.3
  • 108
    • 84861638290 scopus 로고    scopus 로고
    • Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark
    • L.K. Langkilde, A.M. Bergholdt, and M. Overgaard Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark J Med Econ 15 2012 695 703
    • (2012) J Med Econ , vol.15 , pp. 695-703
    • Langkilde, L.K.1    Bergholdt, A.M.2    Overgaard, M.3
  • 109
    • 84862549811 scopus 로고    scopus 로고
    • Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF and ARISTOTLE trials
    • S. Deitelzweig, A. Amin, and Y. Jing et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs. warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF and ARISTOTLE trials J Med Econ 15 2012 776 785
    • (2012) J Med Econ , vol.15 , pp. 776-785
    • Deitelzweig, S.1    Amin, A.2    Jing, Y.3
  • 110
    • 84880141189 scopus 로고    scopus 로고
    • Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation
    • A.R. Harrington, E.P. Armstrong, P.E. Nolan Jr., and D.C. Malone Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Stroke 44 2013 1676 1681
    • (2013) Stroke , vol.44 , pp. 1676-1681
    • Harrington, A.R.1    Armstrong, E.P.2    Nolan, Jr.P.E.3    Malone, D.C.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.